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Abstract
Background: The clonal spread of Acinetobacter baumannii is a global problem, and carbapenems, such as
imipenem, remain the first-choice agent against A. baumannii. Using synergy to enhance the antibiotic activity
of carbapenems could be useful. Here, amlodipine (AML) was tested alone and with imipenem against
A. baumannii isolates.
Methods: Forty-two isolates of A. baumannii were collected. Multilocus sequence typing (MLST) assessed the
genetic relationship of the isolates. The resistance phenotypes were determined using disc diffusion. The
minimum inhibitory concentrations (MICs) of the drugs were determined by broth microdilution. The combined
effects of the drugs were determined by a checkerboard procedure. Metallo-β-lactamase (MBL) was determined
using the MBL Etest.
Results: Forty-two A. baumannii isolates were collected from 42 patients who were mostly older than 65 years
and had long inpatient stays (≥7 days). A. baumannii was mostly recovered from the respiratory system
(N = 35, 83.3%). Most patients (N = 27, 64.3%) received care in intensive care units (ICUs). Disc diffusion testing
demonstrated that A. baumannii susceptibility to polymyxin B was 100%, while susceptibility to other
antimicrobial agents was less than 30%, classifying the isolates into 10 MDR and 32 XDR strains. MLST grouped
the A. baumannii isolates into 4 existing STs and 6 new STs. STn4 carried allele G1, with a T→ C mutation at nt3
on the gpi111 locus. STn5 carried allele A1, possessing A→ C mutations at nt156 and nt159 on the gltA1 locus.
ST195 and ST208 accounted for 68.05% (29/42) of the isolates. Clonal relation analysis showed that ST195 and
ST208 belonged to clonal complex (CC) 92. The inhibitory concentration of imipenem ranged from 0.5 to
32 μg/ml, and that of AML ranged from 40 to 320 μg/ml. In combination, the susceptibility rate of A. baumannii
isolates increased from 16.7% to 54.8% (P = 0.001). In the checkerboard procedure, half of the isolates
(N = 21, 50.0%) demonstrated synergy or partial synergy with the drug combination. The MBL Etest revealed that
1 A. baumannii strain (N = 1, 2.4%) produced MBL.
Conclusions: CC92 was the major clone spreading in our hospital. AML improved the activity of imipenem
against A. baumannii isolates in vitro but did not inhibit MBL.
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Background
Acinetobacter baumannii (AB) has emerged as one of the
most troublesome pathogens in health care institutions
globally. It is characterised by frequent episodes of multi-
drug resistance due to multiple mechanisms, and thera-
peutic options have become increasingly restricted [1-3].
Unfortunately, the present rate of discovery of antibiotics
is much slower than that in the past [4]. This problem is
exemplified by the fact that it is necessary to identify po-
tential reservoirs of the organism and modes of transmis-
sion to control the spread of A. baumannii in hospitals.
To distinguish the outbreak strain from epidemiologically
unrelated acinetobacters, a comparison of isolates at the
subspecies level is required. Multilocus sequence typing
(MLST) is a highly discriminative typing system in which
typing data are translated into a numerical code that can
be obtained in an identical manner at different laborator-
ies using the same protocol. It provides a portable method
that may be suitable for global epidemiologic studies and
that may allow for the recognition of epidemic, multiresis-
tant, and virulent A. baumannii clones and the monitoring
of their national and international spread [1,5,6]. However,
data have been limited in Guangzhou.
Recently, an effective approach has been to explore non-
antibiotic compounds (helper compounds) that express
antibacterial properties, possibly by acting through different
mechanisms from those of existing drugs, either by the en-
hancement of antibiotic activity (synergism) or the reversal
of antibiotic resistance, yielding sensitivity comparable to
that derived from classical antibiotics in previously drug-
resistant microorganisms [7]. Among these non-antibiotics,
amlodipine (AML) is the most promising helper com-
pound. It has been shown to exhibit in vitro activity against
a wide range of bacteria [8-11], but few studies have
reported its potentiating effects on clinical A. baumannii
isolates. In this study, AML was tested, alone and in com-
bination with imipenem, against A. baumannii isolates.
Methods
Bacterial isolates and drugs
A total of 42 isolates of A. baumannii were collected from
patients treated at our hospitals. The Guangzhou First
People’s Hospital Ethics Committee approved the proto-
col, and all of the patients provided informed consent for
inclusion in the study. The total number of beds in the
hospitals was 1571. All of the A. baumannii isolates were
consecutively collected from April 2011 to February 2012
from clinical specimens (respiratory secretion, blood, cere-
brospinal fluid, and urine) from patients who were hospi-
talised in the general wards and intensive care units.
Duplicate isolates from the same patients were excluded.
The isolates were identified using the Vitek 2 (bioMerieux,
Inc. Durham, North Carolina, USA) automated microbiol-
ogy system.
Antibiotic discs (OXOID) were obtained from Melone
Pharmaceutical Co. Ltd. (China). AML was obtained
from Melone Pharmaceutical Co. Ltd. (China), and imi-
penem was obtained from Merck & Co. Inc. Imipenem
was dissolved in phosphate-buffered saline (PBS) accord-
ing to CLSI (M100-S22, 2012) [12]. AML was dissolved
in dimethyl sulfoxide (DMSO) [9].
Multilocus sequence typing (MLST)
MLST was performed on A. baumannii, as described by
Bartual et al. [5]. Briefly, seven housekeeping genes, i.e.,
gltA, gyrB, gdhB, recA, cpn60, gpi, and rpoD, were ampli-
fied, followed by sequencing on the ABI Prism Sequencer
3730 (Applied Biosystems). The sequences of these seven
housekeeping genes were analysed using the Pubmlst data-
base [13]. The sequence type (ST) was designated accord-
ing to the allelic profiles in the database. The eBURST
algorithm (version 3) [14] was used to assign STs to CCs
and to assess the genetic relationship with the definition of
the groups sharing alleles at ≥6 of 7 loci. The CC comprises
a founding ST as a common ancestor, as well as several
other closely related STs descending from the predicted
founding genotype.
Antimicrobial susceptibility testing and
metallo-β-lactamase detection
The strains were stored at −80°C in trypticase soy broth
supplemented with 15% glycerol and were passaged
twice on a blood agar plate before testing. Escherichia
coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853 were used as the control organisms.
All 42 of the isolates were tested against a panel of an-
tibiotics with the disc diffusion method, as recommended
by the Clinical and Laboratory Standards Institute (CLSI;
Table 1 Summary of 42 A. baumannii isolates
Gender (%) Age (%) Hospital ward (%) Type of specimen (%) Inpatient status (%)
Male 30 (71.4%) ≤17 0 (0%) ICU 27 (64.3%) Respiratory 35 (83.3%) ≤2 days 4 (9.5%)
Female 12 (28.6%) 18-65 9 (21.4%) Medical 10 (23.8%) Blood 3 (7.1%) 3-6 days 9 (21.4%)
≥66 33 (78.6%) Surgical 4 (9.5%) Wound 2 (4.8%) ≥7 days 29 (69.1%)
Burn 1 (2.4%) Urine 1 (2.4%)
CSF 1 (2.4%)
ICU, intensive care unit; CSF, cerebrospinal fluid.
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Table 2 Multilocus sequence typing of 42 isolates
Number of isolates Specimens Wards gltA gyrB gdhB recA cpn60 gpi rpoD ST
1 Sputum ICU 1 3 3 2 2 97 3 ST208
2 Blood ICU 1 3 3 2 2 96 5 STn1
3 Sputum ICU 1 3 3 2 2 97 3 ST208
4 Blood ICU 1 3 3 2 2 96 3 ST195
5 BALF RICU 1 3 3 2 2 96 3 ST195
6 Sputum RICU 1 3 3 2 2 96 3 ST195
7 Sputum Respiratory 1 15 3 2 2 153 3 ST457
8 Sputum RICU 1 3 3 2 2 96 3 ST195
9 Sputum ICU 1 3 3 2 2 96 3 ST195
10 Sputum Respiratory 1 3 3 2 2 97 3 ST208
11 Sputum Neurosurgery 1 15 3 2 2 96 3 STn2
12 Sputum RICU 1 3 3 2 2 96 3 ST195
13 Sputum Respiratory 1 3 3 2 2 97 3 ST208
14 Sputum ICU 1 3 3 2 2 96 3 ST195
15 BALF RICU 1 3 3 2 2 96 3 ST195
16 Sputum ICU 1 3 3 2 2 96 3 ST195
17 Wound Gastroenterology 1 3 3 2 2 96 3 ST195
18 Sputum Respiratory 1 3 3 2 2 97 3 ST208
19 Sputum ICU 1 3 3 2 2 97 3 ST208
20 Urine Geriatrics ICU 21 15 3 2 35 111 4 ST254
21 BALF RICU 1 3 3 2 2 96 3 ST195
22 BALF RICU 1 3 3 2 2 96 3 ST195
23 Sputum Respiratory 1 3 3 2 2 97 3 ST208
24 Sputum ICU 1 3 3 2 2 97 3 ST208
25 Sputum RICU 1 3 3 2 2 96 3 ST195
26 Sputum RICU 1 3 3 2 2 96 3 ST195
27 Sputum Neurosurgery 1 81 3 2 2 96 4 STn3
28 Sputum Respiratory 21 15 3 2 35 111 4 ST254
29 Sputum RICU 21 15 3 2 35 111 4 ST254
30 Sputum RICU 1 3 3 2 2 96 3 ST195
31 Sputum Respiratory 1 3 3 2 2 97 3 ST208
32 Sputum Neurosurgery 1 81 3 2 2 96 4 STn3
33 Sputum ICU 1 3 3 2 2 96 3 ST195
34 BALF RICU 1 15 3 2 2 153 3 ST457
35 CSF ICU 1 3 3 2 2 96 3 ST195
36 Sputum Respiratory 21 15 3 2 35 G1 3 STn4
37 Sputum ICU 1 3 3 2 2 96 3 ST195
38 Wound Burn A1 15 3 2 2 153 4 STn5
39 Sputum Geriatrics ICU 21 15 3 2 35 G1 3 STn4
40 Blood Urinary surgery 1 3 3 2 2 96 3 ST195
41 Sputum Nephrology 1 3 3 2 2 97 3 ST208
42 BALF RICU 11 65 3 20 37 96 15 STn6
BALF, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid; ICU, intensive care unit; RICU, respiratory intensive care unit; G1, a new allele that has a T→ C
mutation at nt3 in the gpi111 locus; A1, a new allele possessing two mutations at the gltA1 locus (A → C mutations at nt156 and nt159).
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M100-S22, 2012) [12], to determine the resistance pheno-
type. Multidrug resistance (MDR) was defined as ac-
quired non-susceptibility to at least one agent in three
or more antimicrobial categories, and extensive drug re-
sistance (XDR) was defined as non-susceptibility to at
least one agent in all but two or fewer antimicrobial
categories (i.e., bacterial isolates remaining susceptible
to only one or two categories) [3]. The MBL Etest (bio-
Merieux, Inc. Solna, Sweden) was applied to detect
metallo-β-lactamase (MBL) [15].
The MIC of AML was defined as the lowest concentra-
tion at which no growth was observed. All of the broth
preparations used in the microdilution testing and the
Mueller Hinton broth were freshly prepared and used
within 24 hours. The checkerboard procedure [10] was
used to determine the combined effects of AML and imipe-
nem. Synergy was determined by calculating the fractional
inhibitory concentration (FIC) index as follows: FIC index
= FICA + FICB = [A]/MICA+ [B]/MICB, where [A] is the
concentration of drug A; FICA is the FIC of drug A; and
[B], MICB, and FICB are defined in the same manner for
drug B. The FIC index was interpreted as follows: <0.5,
synergy; 0.5 to 0.75, partial synergy; 0.76 to 1.0, additive ef-
fect; >1.0 to 4.0, indifference; and >4.0, antagonism.
Statistical analysis
SPSS (version 19.0) was used for all of the calculations.
Percentages were compared using the chi-square test. A
P value ≤0.05 in a two-tailed test was considered to indi-
cate statistical significance.
Results
Summary of 42 A. baumannii isolates and MLST
A total of 42 A. baumannii isolates were collected from 42
patients; 30 patients were male, and 12 were female. Most
of the patients were older than 65 years and had long in-
patient stays (≥7 days). The most common site from which
A. baumannii was recovered was the respiratory system
(N= 35, 83.3%), followed by the blood (N = 3, 7.1%). Most
of the patients (N = 27, 64.3%) were receiving care in inten-
sive care units (ICUs), while 15 were in general wards (see
Table 1).
According to the MLST, the 42 A. baumannii isolates
could be grouped into four existing STs [Additional file 1]
Clonal complex 92
Figure 1 Population snapshot of A. baumannii in this study and existing isolates in China. Population snapshot of A. baumannii in this
study and existing isolates in China, based on the data contained in the Pubmlst database [13] as of 27 April 2013, represented by an eBURST
algorithm. Circles represent STs, and their sizes correspond to the number of isolates. The red circle represents the founder ST (ST92). The broken
line indicates clonal complex (CC) 92. The ST labels are coloured as follows: black, STs found only in the Pubmlst database; green, STs found only
in this study; and purple, STs found in both the Pubmlst database and this study. STn3, STn4, STn5, STn6, and ST254 were the singletons in
this study.
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Table 3 Isolates were tested against antibiotics by disc diffusion
Isolate no. SCF TZP CAZ CRO FEP ATM IPM MEM LEV CIP AK DO TGC PB TOB Phenotype/MBL
1 R R R R R R R R R R R R S S R XDR/Neg
2 R R R R R R R R R R R R S S R XDR/Neg
3 R R R R R R R R R R R R S S R XDR/Neg
4 R R R R R R R R R R R R I S R XDR/Neg
5 R R R R R R R R R R R R I S R XDR/Neg
6 R R R R R R R R R R S R I S S MDR/Neg
7 R R R R R R R R R R R R I S R XDR/Neg
8 R R R R R R R R R R R R I S R XDR/Neg
9 R R R R R R R R R R R R I S R XDR/Neg
10 R R R R R R R R R R R R I S R XDR/Neg
11 R R R R R R R R R R R R I S R XDR/Neg
12 R R R R R R R R R R S R I S S MDR/Neg
13 R R R R R R R R R R R R I S R XDR/Neg
14 S R R R R R I I R R R R S S R MDR/Neg
15 R R R R R R R R R R R R I S R XDR/Neg
16 R R R R R R R R R R R R R S R XDR/Neg
17 R R R R R R R R R R R R I S R XDR/Neg
18 R R R R R R R R R R R R I S R XDR/Neg
19 R R R R R R R R R R R R I S R XDR/Neg
20 I R R R R R R R R R R I S S R XDR/Neg
21 R R R R R R R R R R R R R S R XDR/Neg
22 R R R R R R R R R R S R R S S MDR/Neg
23 I R R R R R R R R R R R S S R XDR/Neg
24 S R R R R R S S R R S R I S S MDR/Neg
25 R R R R R R R R R R R R S S R XDR/Neg
26 R R R R R R R R R R R R S S R XDR/Neg
27 R R R R R R S I R R R R I S R MDR/Neg
28 I R R R R R R R R R R R S S R XDR/Neg
29 I R R R R R R R R R R I S S R XDR/Neg
30 R R R R R R R R R R R R I S R XDR/Neg
31 R R R R R R R R R R R R I S R XDR/Neg
32 I R R R I R S S R R R I I S R MDR/Neg
33 R R R R R R R R R R R R I S R XDR/Neg
34 R R R R R R R R R R R R I S R XDR/Neg
35 R R R R R R R R R R R R I S R XDR/Neg
36 I R R R R I R R R R R S S S R MDR/Neg
37 R R R R R R R R R R R R I S R XDR/Neg
38 R R R R R R R R R R R R I S R XDR/Neg
39 R R R R R R R R R R R I S S R XDR/Pos
40 R R R R R R R R R R R R I S R XDR/Neg
Li et al. BMC Infectious Diseases 2013, 13:548 Page 5 of 9
http://www.biomedcentral.com/1471-2334/13/548
(ST195, 1-3-3-2-2-96-3; ST208, 1-3-3-2-2-97-3; ST254, 21-
15-3-2-35-111-4; and ST457, 1-15-3-2-2-153-3) and six
new STs (STn1, 1-3-3-2-2-96-5; STn2, 1-15-3-2-2-96-3;
STn3, 1-81-3-2-2-96-4; STn4, 21-15-3-2-35-G1-3; STn5,
A1-15-3-2-2-153-4; and STn6, 11-65-3-20-37-96-15). STn4
carried a new allele, G1, which had a T → C mutation at
nt3 of the gpi111 locus. STn5 had a new allele, A1, that had
two mutations at the gltA1 locus, which were A→ C muta-
tions at nt156 and nt159. All of the isolates belonging to
ST195 and ST208 accounted for 68.05% (29/42) of the iso-
lates. Clonal relation analysis showed that both ST195 and
ST208 belonged to the globally disseminated CC92 for A.
baumannii (see Table 2 and Figure 1).
Antimicrobial susceptibility testing and
metallo-β-lactamase detection
The data from the disc diffusion testing (see Table 3) dem-
onstrated that the susceptibility of A. baumannii to poly-
myxin B was 100%, while its susceptibility to other
antimicrobial agents was lower than 30%, thus classifying
the 42 A. baumannii isolates into 10 MDR and 32 XDR
strains. In particular, no A. baumannii isolates were sus-
ceptible to ceftazidime, ceftriaxone, cefepime, aztreonam,
levofloxacin, ciprofloxacin, or doxycycline, which have
been routinely used in clinical practice in China. Only one
A. baumannii strain (N = 1, 2.4%) demonstrated MBL pro-
duction, according to the MBL Etest.
Table 4 shows the resistance reversal effects in A. bau-
mannii isolates tested with imipenem. The inhibitory con-
centrations of imipenem alone against all of the strains
tested ranged from 0.5 to 32 μg/ml, and the AML
inhibitory concentrations ranged from 40 to 320 μg/ml. In
combination with AML, the susceptibility rate of A. bau-
mannii isolates to imipenem increased from 16.7% to
54.8% (P = 0.001). Figure 2 clearly shows the effects on imi-
penem MIC changes when different concentrations of
AML were added. The imipenem MICs decreased signifi-
cantly with the addition of 40 μg/ml of AML. Note that the
resistance reversal by AML in combination with imipenem
occurred at concentrations that were much lower than the
MIC90 required for the growth inhibition of 90% of A. bau-
mannii isolates by the compound.
In synergy testing with the checkerboard procedure (see
Table 5), half of the isolates (N = 21, 50.0%) demonstrated
synergy or partial synergy with the imipenem and AML
combination. The FIC index values ranged from 0.375 to
0.75. Ten isolates (N = 10, 23.8%) demonstrated additive ef-
fects; 11 (26.2%) isolates demonstrated indifference; and no
cases of antagonism were observed.
Discussion
A. baumannii infections have become more difficult to
treat due to the emergence of isolates that are resistant to
multiple antimicrobial drugs. Data from the Chinese Net-
work for Bacterial Resistance Surveillance demonstrated
that almost 17% of these isolates were resistant to all of
the antimicrobial agents that are routinely used in clinical
practice and that the susceptibility of A. baumannii to car-
bapenems has decreased to less than 50% [16]. As a conse-
quence, infections caused by A. baumannii strains have
been associated with high mortality and treatment failure
[17]. According to our data, A. baumannii has been widely
Table 3 Isolates were tested against antibiotics by disc diffusion (Continued)
41 I R R R R R S I R R R R R S R MDR/Neg
42 I S R R R R S S I R R I R S R MDR/Neg
Susceptible (%) 2.4 2.4 0.0 0.0 0.0 0.0 11.9 7.1 0.0 0.0 9.5 0.0 28.6 100.0 9.5 -
Metallo-β-lactamase was detected by MBL Etest.
R, resistance; S, sensitivity; I, intermediate; XDR, extensively drug-resistant; MDR, multidrug-resistant; MBL, metallo-β-lactamase; Pos, positive; Neg, negative; PB,
polymyxin B (300 units); TGC, tigecycline (15 μg); IPM, imipenem (10 μg); AK, amikacin (30 μg); TOB, tobramycin (10 μg); MEM, meropenem (10 μg); TZP, piperacil-
lin/tazobactam (100/10 μg); SCF, cefoperazone/sulbactam (70/35 μg); CAZ, ceftazidime (30 μg); CRO, ceftriaxone (30 μg); FEP, cefepime (30 μg); ATM, aztreonam
(30 μg); LEV, levofloxacin (5 μg); CIP, ciprofloxacin (5 μg); DO, doxycycline (30 μg).








MICRange MIC50 MIC90 χ
2 -values P values
AML 40-320 80 160 - - - -
IPM 0.5-32 16 16 7 (16.7%) 35 (83.3%) - -
IPM +10 μg/ml AML 0.5-32 8 16 13 (31.0%) 29 (69.0%) 2.363 0.200
IPM +20 μg/ml AML 0.5-32 8 16 15 (35.7%) 27 (64.3%) 3.941 0.081
IPM +40 μg/ml AML <0.5-32 4 16 23 (54.8%) 19 (45.2%) 13.274 0.001
MIC, minimum inhibitory concentration; MIC50 and MIC90, MICs for 50% and 90% of strains, respectively;
anonsusceptible, including intermediate resistance;
bstatistical analysis compared with the IPM group.
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distributed in our hospital and has been isolated from
the respiratory system, blood, wounds, urine, and cerebro-
spinal fluid, especially from ICU patients who are older
and have longer inpatient stays, similar to the results re-
ported in many other studies [1,18-20]. The susceptibility
of these isolates to imipenem was 16.1% (according to the
MIC method). Only 1 (2.4%) MBL-producing A. bauman-
nii strain was found in our study, which was similar to the
findings of Hui Wang [21], in which only 1 isolate among
221 nonrepetitive imipenem-resistant clinical isolates of
Acinetobacter spp. carried the bla(IMP-8) MBL gene. The
present study demonstrated that MBL was not the pri-
mary cause of A. baumannii resistance to imipenem in
our hospital. Class D β-lactamases, the modification of
penicillin-binding proteins and porins, or the upregulation
of the AdeABC efflux system may have played more im-
portant roles in their potential resistance mechanisms
[22]; thus, further investigation is needed.
MLST is an unambiguous typing method that has
achieved notable success in global epidemiological investi-
gations of A. baumannii [5,6]. Recently, some studies
[6,23-26] have revealed that CC92 (previously known as
CC22) has worldwide dissemination. The ST92 A. bauman-
nii isolate is the most common clone, and it has been pre-
dicted to be the founder of this clonal complex. Yiqi Fu
et al. [26] confirmed that CC92 represented the most epi-
demic STs in China. In addition to ST92, the other STs be-
long to CC92 and vary by area. A study by He et al. [25]
showed that more ST138 isolates are associated with ST92
in western China. However, results from Qiao Zhong et al.
[23] indicated that ST75, accompanied by ST92, may be
the most common epidemical sequence types in eastern
China. In our study, we assumed that ST195 and ST208
may be more common in southern China. These differ-
ences may be caused by different antibiotic usage habits,
which could have influenced the evolutionary direction of
ST92. Why has this clonal complex been so successful?
Studies have shown that antibiotic susceptibility of CC92 is
variable [27]. These findings may suggest that adaptation to
the hospital environment, as well as antibiotic resistance,
has been more important for the success of A. baumannii
as a nosocomial pathogen.
Because imipenem remains the first-choice agent in
China against A. baumannii strains [28], finding a way to
enhance the antibiotic activity (synergism) of carbapenems
against A. baumannii strains could be encouraging. Cal-
cium channel blockers (CCBs) are a heterogeneous class
of drugs used for the control of hypertension, angina, and
cardiac arrhythmias [29]. However, many studies have re-
ported a wide variety of broad-spectrum antibacterial
Figure 2 The change in the imipenem MIC by adding AML. Figure 2 shows the distribution of imipenem MICs. The change in the imipenem
MIC with the addition of 10, 20, and 40 μg/ml of AML compared with the MIC resulting from no AML addition. The imipenem MICs decreased
significantly with the addition of 40 μg/ml of AML.




<0.5 Synergy 0.5 to 0.75 partial synergy 0.76 to 1.0 additive effect >1.0 to 4.0 indifference >4.0 antagonism
Imipenem + AML 6 (14.3%) 15 (35.7%) 10 (23.8%) 11 (26.2%) 0 (0%)
The concentrations of imipenem and AML used in the checkerboard procedure depended on the MICs of each A. baumannii isolate tested.
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activities of CCBs [30], the most powerful of which was
AML. Kumar [9] reported in vitro antimicrobial activity of
AML against several Gram-positive and Gram-negative
standard and clinical strains, including Bacillus pumilus
NCTC 8241, Staphylococcus aureus NCTC 6571, Escheri-
chia coli K12Row, Salmonella typhimurium NCTC74, Shi-
gella dysenteriae 7 NCTC 519/66, Shigella sonnei 1NCTC
5/59, Shigella flexneri 4a24, Shigella boydii 8 NCTC 254/
66, Klebsiella pneumoniae 14, Vibrio cholerae ATCC
14033, and P. aeruginosa APC. The inhibitory concentra-
tions of AML against most of the strains tested ranged
from 25 to 200 μg/ml, but its effects on P. aeruginosa, E.
coli, and K. pneumoniae were limited, and the inhibitory
concentrations were >800, >800, and 400 μg/ml, respect-
ively. A further study demonstrated that AML in combin-
ation with streptomycin had a synergistic effect [10]. In
addition to its in vitro and in vivo activity against Gram-
positive and Gram-negative bacteria, AML showed a two-
to eightfold reduction in its MIC when combined with
streptomycin, and vice versa [10]. Similarly, when paired
with levofloxacin, AML showed potential synergistic effects
in the eradication of P. aeruginosa biofilms [11]. Our re-
search demonstrated the antimicrobial activities of AML
against clinical A. baumannii strains, and the MICs ranged
from 40 to 320 μg/ml. In combination with imipenem, half
of the isolates (N = 21, 50.0%) demonstrated synergy or par-
tial synergy. Further investigations, such as the develop-
ment of a time-killing curve, which may demonstrate
killing synergistic effects against A. baumannii strains, are
needed.
To date, research on the antimicrobial efficacy of AML
has been conducted only in vitro and in animal models.
Chronic toxicity tests with healthy mice showed that the
therapeutic dose of AML (10 mg/kg) was within a safe
and acceptable margin. Low doses of AML at 1.5 mg/kg/
day continue to show good efficacy in mice [7]. According
to our study results, AML must be used at doses of up to
40 μg/ml to improve the activity of imipenem against A.
baumannii isolates. However, in humans, the recom-
mended dose of AML is much lower, at only 10 mg/day
(Cmax 6.14 ng/ml) as an antihypertensive agent, thus cur-
rently limiting the clinical application of AML [31]. How-
ever, AML has been able to cure highly virulent bacterial
infections in mice. This ability suggests that AML could
be employed as a ‘lead compound’ to synthesise more ac-
tive novel agents that may be free of side effects, such as
hypotension. Because both drugs have been satisfactorily
used for a long time in clinical medicine for different pur-
poses, their combination in humans is feasible.
Conclusions
CC92 was the major clone that spread in our hospital. AML
improved the activity of imipenem against A. baumannii
isolates in vitro, but it did not work by inhibiting MBL.
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